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Abstract
Background: Androgen withdrawal in normal prostate or androgen-dependent prostate cancer
is associated with the downregulation of several glycolytic enzymes and with reduced glucose
uptake. Although glycogen metabolism is known to regulate the intracellular glucose level its
involvement in androgen response has not been studied.
Methods: We investigated the effects of androgen on glycogen phosphorylase (GP), glycogen
synthase (GS) and on glycogen accumulation in the androgen-receptor (AR) reconstituted PC3 cell
line containing either an empty vector (PC3-AR-V) or vector with HPV-E7 (PC3-AR-E7) and the
LNCaP cell line.
Results: Androgen addition in PC3 cells expressing the AR mimics androgen ablation in androgen-
dependent prostate cells. Incubation of PC3-AR-V or PC3-AR-E7 cells with the androgen R1881
induced G1 cell cycle arrest within 24 hours and resulted in a gradual cell number reduction over
5 days thereafter, which was accompanied by a 2 to 5 fold increase in glycogen content. 24 hours
after androgen-treatment the level of Glucose-6-P (G-6-P) had increased threefold and after 48
hours the GS and GP activities increased twofold. Under this condition inhibition of glycogenolysis
with the selective GP inhibitor CP-91149 enhanced the increase in glycogen content and further
reduced the cell number. The androgen-dependent LNCaP cells that endogenously express AR
responded to androgen withdrawal with growth arrest and increased glycogen content. CP-91149
further increased glycogen content and caused a reduction of cell number.
Conclusion: Increased glycogenesis is part of the androgen receptor-mediated cellular response
and blockage of glycogenolysis by the GP inhibitor CP-91149 further increased glycogenesis. The
combined use of a GP inhibitor with hormone therapy may increase the efficacy of hormone
treatment by decreasing the survival of prostate cancer cells and thereby reducing the chance of
cancer recurrence.
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Background
Androgen withdrawal leads to apoptosis of normal pros-
tate cells and is the principal therapy to treat advanced
prostate cancer [for a review, [1]]. Metabolic events
known to be associated with androgen withdrawal are
reduction in glucose uptake, downregulation of several
glycolytic enzymes and of some key enzymes of the pen-
tose-phosphate shunt [2-5]. Androgen withdrawal led to
transcriptional downregulation of the pyruvate dehydro-
genase E1 alpha (PDH E1α ) gene in rat ventral prostate
and in PC3 prostate cancer cells transiently transfected
with the androgen receptor. Reduced transcription of
PDH E1α  is associated with a reduction of the glucose oxi-
dative pathway [6]. In contrast, androgen stimulated CO2
production derived from glucose [2]. These results suggest
that glucose transporters and several catabolic enzymes
are regulated in an androgen-dependent manner.
Glycogen metabolism is regulated by intermediates of gly-
colysis, by covalent modification and by glycogen and
purines. The two major enzymes GS and GP are controlled
by phosphorylation and allosterically by effector mole-
cules [7-9]. Glycogen synthase (GS) in its phosphorylated
form is inactive but can be activated allosterically by G-6-
P. This can facilitate the dephosphorylation by a glycogen-
bound PP1-type phosphatase to the active form [10,11].
Active GS is inactivated by phosphorylation by several
important protein kinases: casein kinase II, calmodulin-
dependent kinases, protein kinase A (PKA), protein kinase
C (PKC) [12,13]. Glycogen synthase kinase 3 (GSK-3), a
major kinase inactivating GS, phosphorylates several sites
on GS but only when GS has been phosphorylated at
other sites [14]. Partial dephosphorylation of a specific N-
or C-terminal residue increases the sensitivity of GS to
activation by G-6-P [15].
Glycogen phosphorylase (GP) also exists in two forms,
the active phosphorylated a-form (GP-a) and the inactive
b-form (GP-b). cAMP and calcium stimulate the activa-
tion of GP through PKA and phosphorylase (PHOS)
kinase, which seems to be the only kinase phosphorylat-
ing GP [16]. Muscle GP is allosterically activated by the
binding of AMP, whereas G-6-P and glucose are allosteric
inhibitors [9].
We have recently shown that the cyclin-dependent kinase
inhibitor flavopiridol, which is in clinical trials as an anti-
cancer agent, is also a potent GP inhibitor and binds to the
purine-nucleotide inhibitor-binding site of GP [17,18].
Inhibition of glycogen degradation by the specific GP
inhibitor CP-91149 also growth inhibited cells that
expressed high levels of brain GP but not cells expressing
low levels of brain GP [19]. CP-91149 binds at a site
located at the subunit interface in the region of the central
cavity of the dimeric structure and stabilizes the inactive
form of GP [20-23], These observations raised the possi-
bility that glycogen metabolism, and in particular brain
GP, may be a potential target for anticancer therapy.
Therefore, to understand the regulation and role of glyco-
gen metabolism in prostate cancer in response to andro-
gen we measured intracellular glycogen stores, the
activities of GS and GP and G-6-P in prostate cancer cell
lines. Our results indicate that glycogen accumulation and
reduction in cell growth are associated with the androgen
response of prostate cancer cells and can be further
enhanced by GP inhibition with the GP inhibitor CP-
91149. Thus androgen-dependent growth arrest and cell
death can be further enhanced by GP inhibition.
Methods
Cell lines and cell culture
The construction and characterization of PC3 cells recon-
stituted with the androgen receptor (AR) has been
reported [24]. For these experiments, PC3-AR cells were
stably transfected with vector pZ16E67 BN containing the
human papilloma virus E7 protein cDNA (PC3-AR-E72
and E73) or vector pZipNeoSV(X)1 alone (PC3-AR-V1
and V2)[25]. LNCaP cells were obtained from ATCC and
experiments were performed with cells around passage
23. All cells were grown in RPMI 1640 lacking phenol red
supplemented with charcoal-stripped 5% fetal bovine
serum and containing penicillin (100 units/ml), and
streptomycin (100 µg/ml). Stably transfected PC3-AR-E7
or V cells were maintained with 100 µg/ml hygromycin
and 500 µg/ml G418. Cultures of LNCaP cells were sup-
plemented with 4 nM of the stable testosterone derivative
R1881.
Androgen response was induced by either adding 4 nM
R1881 (PC3-AR-E7 or V) or by omitting androgen from
the culture medium (LNCaP). PC3-AR-E7 or V cells were
plated in a density of 5 × 105 cells per 100 mm dish and
LNCaP in a density of 3 × 105 cells per 100 mm dish. Cells
were kept under 95% air and 5% CO2 at 37°C in a humid-
ified incubator.
Glycogen synthase (GS), phosphorylase (GP) activity 
assays, glycogen and G-6-P determination
GS assays were performed as described with some modifi-
cations [26]. For the assay cells from one 100 mm plate
were harvested, washed in PBS and lysed in lysis buffer
(50 mM Tris/HCl (pH 7.5), 250 mM NaCl, 0.1% NP40, 5
mM EDTA, 50 mM NaF, 1 mM for phenyl-methyl-sulfo-
nyl-fluoride, protease inhibitor cocktail (Boehringer-
Mannheim)). Cell lysates were diluted equally with GS
dilution buffer. The reaction was started by adding 25 µl
assay buffer to 25 µl of the lysate. The assay buffer con-
tained 5 mM UDP-glucose and 1 µCi/ml of [U-14C]UDP-
glucose. 10 mM G-6-P was added to determine the activity
of allosterically activated GS. The reaction was performedBMC Urology 2005, 5:6 http://www.biomedcentral.com/1471-2490/5/6
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at 30°C for 15 min and stopped by pipetting the mixture
on a p81 Whatman filter. The filters were immersed in
66% EtOH, washed several times in EtOH, once in ace-
tone, air-dried and counted in a liquid scintillation coun-
ter (LKB Wallac). GP activity and glycogen content were
determined as described with modifications [17,27,28].
The G-6-P concentration was determined in the following
way. Nine 100 mm petri dishes were prepared for the iso-
lation of G-6-P and cells collected, sedimented by centrif-
ugation and 0.75 ml 6% perchloric acid added to the cell
pellet. Samples were homogenized, iced for 10 min, vor-
texed and centrifuged at 6000 rpm for 15 min in the Sor-
vall at 4°C. 0.6 ml of supernatant was neutralized by
adding 134 ul of 4 M KOH/0.8 M imidazole. A pH around
7 was confirmed with pH paper. Samples were then cen-
trifuged for 20 min to precipitate the salts. The superna-
tant was stored at -80°C until assayed in a Hitachi
Fluorometer. The reaction was started by adding G-6-P
dehydrogenase from Leuconostroc mesenteroides and incu-
bated at room temperature for 25 min. Samples were
measured before the reaction and immediately after-
wards. The excitation wavelength was 365 nm and the
emission wavelength 435 nm.
Flow cytometric analysis
Cells were fixed with 70% ethanol, DNA was stained with
propidium iodide. The intensity of fluorescence was
measured using a Becton Dickenson flow cytometer at
488 nm for excitation and at 650 nm for emission [29].
The cell cycle profile was analyzed using Modifit's Sync
Wizard (Verity Software Inc.).
Results
Growth, cell cycle arrest and glycogen content in PC3-AR-
E7 and PC3-AR-V cells treated with R1881
The effects of androgen on glycogen metabolism in pros-
tate cancer were investigated using the PC3-AR model
[30,31]. PC3 cells do not express the androgen receptor
(AR) and are, therefore, androgen-independent. Paradox-
ically, when PC3 cells are reconstituted with AR (PC3-AR),
they become sensitive to the addition of androgen by exit-
ing from the cell cycle and undergoing apoptosis [24].
This phenomenon is until now unexplained. Therefore, to
induce an androgen response, the androgen R1881 was
added to PC3-AR (PC3-AR-V) cells. Glycogen content nor-
malized to cell count was determined after different incu-
bation times (Fig. 1A). Glycogen content doubled when
cells were incubated with R1881 for 24 hours and further
increased upon longer incubation times with R1881. This
effect was not observed in PC3 cells lacking AR and treated
with R1881 for up to 72 hours.
Androgen-independent prostate cancer frequently
acquires the loss of a functional retinoblastoma protein
(pRb) [32]. Loss of pRb leads to a reduction of androgen-
dependent gene expression, which has been interpreted as
a possible mechanism for the androgen-independent
growth of these cells [33]. Therefore, we tested whether
inactivation of pRb reverses the sensitivity of PC3-AR cells
to androgen with respect to glycogen accumulation. PC3-
AR cells were constructed that expressed the HPV-E7 pro-
tein, which binds and inactivates pRb (PC3-AR-E7)
[34,35]. PC3-AR cells transfected with the empty vector
(PC3-AR-V) were used as a control. As shown in Fig. 1A,
PC3-AR-E7 cells show a similar 2 to 5 fold increase in the
glycogen content as do the control cells lacking E7 expres-
sion. The two cell lines differ in their basal glycogen con-
tent, which is about 50% lower in PC3-AR-E7. At 120
hours we observed less glycogen accumulation in the
PC3-AR-E7 cells compared to control.
We further compared the number of viable cells using
manual cell counts coupled with trypan blue staining
when the cell lines were treated with R1881 (Fig. 1B). We
tested two E7 and two control transfectants. A gradual
reduction in cell number was observed both in PC3-AR-
V1/V2 and PC3-AR-E72/E73 cells upon R1881 treatment.
However, the PC3-AR-E7 clones showed slightly higher
viable cell counts than the control clones following 72
and 120 hours of R1881 treatment. Growth inhibition
was not observed for R1881-treated PC3 cells lacking AR
and demonstrates that it requires the presence of AR. Cell
cycle arrest for both cell lines 24 hours upon R1881 treat-
ment was identified using FACS analysis (Fig. 2). The
number of S-phase cells decreased in both R1881-treated
PC3-AR cell lines while the number of G1-phase cells
increased.
GS activity in PC3-AR cells treated with R1881
The increase in glycogen content suggests enhanced glyco-
genesis in androgen-treated PC3-AR cells. The enzyme cat-
alyzing glycogenesis is GS, which exists in two forms, an
active unphosphorylated form, and an inactive phospho-
rylated form, which can be allosterically activated by G-6-
P [10]. To determine GS activity, cell extracts were pre-
pared from PC3-AR-E7 cells, which were either untreated
or treated with R1881 for 72 hours. GS activity measured
in the absence of G-6-P was hardly detectable in untreated
and R1881-treated cells suggesting that GS was predomi-
nantly present in the inactive phosphorylated state despite
hormonal treatment of cells (Fig. 3A). When the GS assay
was performed in the presence of G-6-P, which allosteri-
cally stimulates GS, an 18 and 35 fold higher GS activity
was observed in control and R1881-treated cells respec-
tively. To determine whether the increase in G-6-P acti-
vated GS occurs early upon exposure of cells to R1881
PC3-AR-E7 cells were harvested for GS assays in short time
intervals (Fig. 3B). G-6-P-activated GS did not show an
increase compared to untreated cells (0) until 48 hours
after exposure of cells to R1881 indicating that theBMC Urology 2005, 5:6 http://www.biomedcentral.com/1471-2490/5/6
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The effect of R1881 on viable cell number, cell cycle and glycogen content of PC3-AR-V and PC3-AR-E7 cells Figure 1
The effect of R1881 on viable cell number, cell cycle and glycogen content of PC3-AR-V and PC3-AR-E7 cells. Two independently iso-
lated control (PC3-AR-V1 and PC3-AR-V2) or HPV-E7 expressing clones (PC3-AR-E72 and PC3-AR-E73) were tested. R1881 
was added to exponentially growing cells to a final concentration of 4 nM and cells were further incubated for the indicated 
times. PC3 cells, which lack AR were used as a negative control. Cell samples were removed A) to determine the glycogen 
content and B) to determine the viable cell count using the trypan blue assay.
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increase in GS activity is not an immediate response to
androgen. However, the observed twofold glycogen
increase within 24 hours upon R1881 treatment suggests
the possibility that androgen-treatment results in an
increase in the intracellular G-6-P content, which alloster-
ically stimulates GS activity. We determined the G-6-P lev-
els in untreated and in 24 hours R1881-treated PC3-AR-
E7 cells. We found a 3 fold increase in the G-6-P content
normalized to mg protein (Fig. 3C). These results indicate
that enhanced glycogenesis in R1881-treated could be the
result of GS stimulation by G-6-P.
GP activity in PC3-AR cells treated with R1881
Glycogen accumulation can also result from inhibition of
glycogenolysis, which involves GP. GP exists in two
forms, an active phosphorylated (GP-a) and an inactive
form (GP-b), which can be regulated by allostery [9]. We
examined the GP-a activity in untreated and R1881-
treated cells. The GP-a activity normalized to protein in
R1881-treated PC3-AR-V and PC3-AR-E7 cells increased
slightly within 24 hours and doubled after 72 hours com-
pared to untreated cells demonstrating activation of GP by
androgen (Fig. 4). Since despite an increase in GP-activity
the glycogen content increased, this suggests steady-state
increase in glycogenesis. It is likely that GP-a may be par-
tially inhibited allosterically by G-6-P, which increases in
R1881-treated cells.
Glycogenolysis inhibition by CP-91149 in R1881-treated 
PC3-AR cells
We showed that stimulation of glycogenesis, which
exceeds glycogenolysis appeared to be responsible for the
glycogen accumulation that inversely correlated with cell
growth upon androgen-treatment in PC3-AR-V and PC3-
AR-E7 cells. To test whether the inhibition of glycogenol-
ysis further enhances the cellular response to androgen,
GP activity was blocked with the selective GP inhibitor
CP-91149. CP-91149 allosterically stabilizes the inactive
conformation of human liver GP and induces dephospho-
rylation of GP-a [21-23]. We previously showed that CP-
91149 also inhibits brain GP, which is the GP isoform
expressed in all cell lines we have so far analyzed includ-
ing PC3 cells [19]. PC3-AR-V and PC3-AR-E7 cells were
treated with 30 µM CP-91149, which is a sufficient con-
centration to inhibit GP in several different cell lines
including PC3 [[19] and data not shown]. PC3-AR-V and
PC3-AR-E7 cells were both growth-arrested in the pres-
ence of CP-91149 without androgen-treatment (Fig. 5B).
In this particular experiment, untreated cells were har-
vested 24 hours after the start of the incubation to avoid
the effect of high cell density while treated cells were har-
vested after 72 hours. The actual number of cells from the
untreated culture would, therefore, be much higher after
72 hours compared to the CP-91149-treated culture
(about double). This demonstrates inhibition of cell
growth by CP-91149 treatment alone. The cell number of
R1881-treated cultures was about 50% smaller compared
to CP-91149-treated cultures. When cells were treated
with both R1881 and CP-91149 simultaneously, the cell
number was reduced to about 50% of R1881-treatment
alone consistent with an additive effect of CP-91149 on
R1881-treatment. These results indicate that glycogenoly-
sis in cells treated with R1881 is still enough to support
growth and/or survival as the intracellular glycogen con-
tent correlated inversely to the number of cells (Fig. 5A).
Untreated cells had the lowest glycogen content as nor-
malized to cell count while the glycogen level doubled in
CP-91149-treated cells. A 4-7 fold increase in the glycogen
content was achieved by R1881-treatment. CP-91149 and
R1881-double treatment resulted in 35–40% additional
increase in glycogen content. This result further confirmed
a tight correlation between glycogen accumulation and
cell growth of R1881-treated PC3-AR cells and demon-
strated that blockage of glycogenolysis by inhibition of
FACS analysis of R1881-treated PC3-AR-V and PC3-AR-E7  cells Figure 2
FACS analysis of R1881-treated PC3-AR-V and PC3-AR-E7 cells. 
R1881 was added to exponentially growing cells to a final 
concentration of 4 nM and cells were further incubated for 
24 hours. Cells were then harvested and processed for FACS 
analysis.
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Determination of glycogen synthase activities in PC3-AR-E7 cells Figure 3
Determination of glycogen synthase activities in PC3-AR-E7 cells. R1881 was added to cells to a final concentration of 4 nM. Samples 
were removed at the indicated times. Activities are in nMol/min/mg protein. A) GS activity was determined from cells treated 
with R1881 for 72 hours and from untreated cells. GS activities were determined in the absence (-G-6-P) and presence (+G-6-
P) of G-6-P. B) GS activities in the presence of G-6-P was determined from cells treated with R1881 for the times indicated. C) 
The G-6-P content was determined in untreated and 24 hours R1881-treated PC3-AR-E7 cells.
1
2
3
4
R1881 - +
n
M
o
l
1
4
C
-
U
D
P
-
G
l
u
c
o
s
e
/
m
i
n
/
m
g
0.4
0.8
1.2
A
0
2
4
6
048 1 2 2 4 4 8
+R1881/hours
n
M
o
l
1
4
C
-
U
D
P
-
G
l
u
c
o
s
e
/
m
i
n
/
m
g
B
C
R1881 - +
n
M
o
l
G
l
u
c
o
s
e
-
6
-
P
/
m
g
P
r
o
t
e
i
n
-G6P
+G6PBMC Urology 2005, 5:6 http://www.biomedcentral.com/1471-2490/5/6
Page 7 of 10
(page number not for citation purposes)
GP-a with CP-91149 enhanced the effect of androgen on
both PC3-AR-V and PC3-AR-E7 cells.
R1881 withdrawal results in glycogen accumulation in 
LNCaP cells
The effects of androgen on the glycogen content was then
evaluated in the androgen-dependent prostate cancer cell
line LNCaP. The LNCaP cell line expresses a functional AR
endogenously and growth arrests in the absence of andro-
gen. LNCaP cells were cultured for seven days in the pres-
ence and absence of R1881 with regular medium changes.
Cells ceased to grow and the intracellular glycogen con-
tent increased compared with cells grown in the presence
of R1881 (Fig. 6). LNCaP cells were similarly growth-
arrested as PC3-AR cells when glycogenolysis was inhib-
ited with CP-91149 (Fig. 6B). We observed no difference
in the glycogen level from control cells grown in the pres-
ence of R1881 and absence of CP-91149. The most likely
explanation is that control cells were grown to high den-
sity, which has been reported to result in decreased GP-a
activity in colon cancer cells [36]. When R1881 was
removed from the medium and simultaneously CP-
91149 was added, the number of cells further reduced and
the cell count normalized to the glycogen level increased
to a higher extent than either treatment alone. Thus the
inverse relationship between intracellular glycogen accu-
mulation and cell growth and the additive effect of GP
inhibition in androgen-deprived cells were reproduced in
the androgen-dependent prostate cancer LNCaP cell line.
Discussion
In this paper we describe the effect of androgen on glyco-
gen metabolism in different prostate cancers. We used
Glycogen phosphorylase activity in PC3-AR-V/E7 cells Figure 4
Glycogen phosphorylase activity in PC3-AR-V/E7 cells. R1881 was 
added to cells to a final concentration of 4 nM and GP activi-
ties were determined in the absence of AMP, which reflects 
the activities of the levels of activated GP. The in vitro enzyme 
activity for each sample was followed over a time period of 5 
min. The activities are expressed in nMol/min/mg protein.
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Determination of viable cell number and glycogen content in  PC3-AR-V and PC3-AR-E7 treated with R1881 and/or CP- 91149 Figure 5
Determination of viable cell number and glycogen content in PC3-
AR-V and PC3-AR-E7 treated with R1881 and/or CP-91149. Cells 
were either treated with 4 nM R1881 or 30 µM CP-91149 or 
both simultaneously. Control cells are those grown in the 
absence of R1881 and CP-91149 and were harvested after 24 
hours. Treated cells were harvested 48 hours later and the 
total incubation time is 72 hours. A) The glycogen content 
normalized to the number of cells and B) the number of via-
ble cells was determined.
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PC3-AR-V and PC3-AR-E7 cells, which ectopically
expresses AR and in case of PC3-AR-E7 the HPV-E7 pro-
tein. Additionally, LNCaP, which maintains a functional
AR, was tested for glycogen content and its correlation to
the number of cells. The PC3-AR-V and PC3-AR-E7 cell
lines demonstrated a response to androgen leading to G1
arrest with a corresponding increase in the glycogen con-
tent (2 to 5 fold). PC3 cells lacking AR did not increase
glycogen content in response to androgen. PC3 (AR-) cells
demonstrate that intracellular glycogen content corre-
sponds with the growth and/or survival of cells harbour-
ing a functional AR. Intracellular stores of glycogen
correlated inversely with the cell number: when cell num-
bers are low the glycogen content is high. This inverse rela-
tionship suggests that glycogenesis participates in growth
arrest. However, glycogenesis is most likely not sufficient
to induce ATP-dependent apoptosis, as the inhibition of
glycogenolysis with the GP inhibitor CP-91149 does not
induce cell death in these prostate cell lines. Glycogen
content normalized to the number of cells is about 50%
higher in PC3-AR cells treated with R1881 than treated
with CP-91149. The additional increase in glycogen con-
tent of R1881-treated PC3-AR-V/E7 cells upon CP-91149
treatment further results in a reduction of cell number by
growth inhibition and reduction in cell viability, which
suggests that a certain intracellular glycogen content has
to be reached to affect cell viability. Alternatively, certain
effects of hormone treatment on cell survival may be
enhanced by inhibition of glycogenolysis using CP-
91149. Similarly, LNCaP cells responded with glycogen
accumulation and growth arrest upon androgen removal,
which was further enhanced by the GP inhibitor CP-
91149.
One explanation of reduced cell viability in conjunction
with glycogen content could be the increase in G-6-P in
response to androgen. G-6-P is a key metabolite allosteri-
cally activating GS [12]. The G-6-P content was about 3
fold higher 24 hours after androgen addition in PC3-AR
cells compared to untreated cells. The increase in the G-6-
P level was most probably a consequence of the decrease
in activity of some key glycolytic enzymes as well as G-6-
P dehydrogenase, which have been reported to be under
androgen control [3]. We can, however, not exclude the
presence of another allosteric GS activator nor partial acti-
vation of GS, which would sensitize GS to allosteric
Determination of viable cell number and glycogen content of LNCaP cells deprived of R1881 in the absence or presence of CP- 91149 Figure 6
Determination of viable cell number and glycogen content of LNCaP cells deprived of R1881 in the absence or presence of CP-91149. 
Control cells were grown in the presence of R1881. Treated cells were either deprived of R1881 and/or treated with 30 µM 
CP-91149. The total length of the experiment was seven days. A) The glycogen content was determined and normalized to the 
number of cells. B) The number of viable cells was determined.
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activation. The increase in G-6-P could also explain why
an increase in activated GP (GP-a) in PC3-AR cells upon
androgen treatment did not prevent the increase in glyco-
gen content, since G-6-P is a GP-a inhibitor [37,38]. How-
ever, the fact that CP-91149 increased the glycogen
content twofold more in androgen-treated PC3-AR cells
shows that there was still GP-a activity. CP-91149 is
known to cause GP-a dephosphorylation and partial GS-
activation [39].
Conclusion
Glycogenesis is part of the androgen response in prostate
cancer and further inhibition of glycogen phosphorylase
by a specific inhibitor reduces the cell number suggesting
that glycogenolysis contributes to cell survival. Thus inhi-
bition of glycogenolysis in combination with hormone
therapy may be a more effective treatment for advanced
prostate cancer than hormone therapy alone.
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